EBS:NYE-Emergent Biosolutions Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 6.01

Change

-0.16 (-2.59)%

Market Cap

USD 1.16B

Volume

1.04M

Analyst Target

USD 112.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Emergent BioSolutions Inc is a specialty biopharmaceutical company It develops, manufactures, and delivers a portfolio of medical countermeasures for government agencies in the areas of biological and chemical threats and emerging infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-17 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.34 (+1.74%)

USD 89.02B
HLN Haleon plc

N/A

USD 48.04B
TAK Takeda Pharmaceutical Co Ltd A..

+0.07 (+0.48%)

USD 47.42B
RDY Dr. Reddy’s Laboratories Ltd..

+0.42 (+0.53%)

USD 13.05B
CTLT Catalent Inc

+0.43 (+0.72%)

USD 10.91B
ELAN Elanco Animal Health

+0.07 (+0.51%)

USD 6.96B
BHC Bausch Health Companies Inc

+0.08 (+1.00%)

USD 2.98B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.01 (+0.12%)

USD 2.58B
CPHI China Pharma Holdings Inc

+0.03 (+12.55%)

USD 3.66M
YCBD cbdMD Inc

N/A

USD 1.73M

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 21.50 % 0.00 %

+0.55 (+1.47%)

USD 0.05B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 21.50 % 0.00 %

+0.59 (+1.47%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 21.35 % 0.00 %

+0.30 (+1.47%)

USD 0.09B
EBNK:CA Evolve European Banks Enh.. 5.01 % 0.00 %

N/A

CAD 3.39M
IVES Amplify ETF Trust 3.51 % 0.00 %

+0.32 (+1.47%)

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

+0.64 (+1.47%)

USD 0.13B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

N/A

USD 0.13B
LDEU:LSE L&G Quality Equity Divide.. 1.39 % 0.00 %

+0.16 (+1.47%)

USD 0.04B
LGGE:XETRA L&G Quality Equity Divide.. 1.38 % 0.00 %

+0.18 (+1.47%)

USD 0.03B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+11.40 (+1.47%)

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.97 % 0.00 %

+0.14 (+1.47%)

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 0.94 % 0.00 %

+0.08 (+1.47%)

USD 0.26B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.84 (+1.47%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 150.42% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.42% 100% F 100% F
Trailing 12 Months  
Capital Gain -28.62% 19% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.62% 19% F 8% B-
Trailing 5 Years  
Capital Gain -87.08% 8% B- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.08% 8% B- 2% F
Average Annual (5 Year Horizon)  
Capital Gain -29.37% 6% D- 2% F
Dividend Return -29.37% 6% D- 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.08% 25% F 12% F
Risk Adjusted Return -44.45% 13% F 8% B-
Market Capitalization 1.16B 19% F 39% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.40 40% 8%
Price/Book Ratio 0.17 100% 99%
Price / Cash Flow Ratio -9.28 100% 93%
Price/Free Cash Flow Ratio -1.65 81% 84%
Management Effectiveness  
Return on Equity -60.57% 25% 7%
Return on Invested Capital -6.68% 20% 13%
Return on Assets -0.38% 25% 20%
Debt to Equity Ratio 32.28% 82% 71%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector